X Square Capital LLC Acquires 41,408 Shares of Hims & Hers Health, Inc. $HIMS

X Square Capital LLC increased its holdings in shares of Hims & Hers Health, Inc. (NYSE:HIMS) by 9.7% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 468,999 shares of the company’s stock after buying an additional 41,408 shares during the period. Hims & Hers Health comprises approximately 5.0% of X Square Capital LLC’s portfolio, making the stock its largest position. X Square Capital LLC’s holdings in Hims & Hers Health were worth $15,228,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in the business. Vanguard Group Inc. boosted its position in Hims & Hers Health by 7.2% during the 4th quarter. Vanguard Group Inc. now owns 20,925,666 shares of the company’s stock worth $679,456,000 after buying an additional 1,407,651 shares during the period. Capital World Investors boosted its position in Hims & Hers Health by 1.2% during the 3rd quarter. Capital World Investors now owns 18,783,194 shares of the company’s stock worth $1,065,399,000 after buying an additional 223,892 shares during the period. Farallon Capital Management LLC boosted its position in Hims & Hers Health by 30.8% during the 3rd quarter. Farallon Capital Management LLC now owns 10,746,852 shares of the company’s stock worth $609,561,000 after buying an additional 2,533,271 shares during the period. State Street Corp boosted its position in Hims & Hers Health by 1.9% during the 3rd quarter. State Street Corp now owns 7,173,214 shares of the company’s stock worth $406,865,000 after buying an additional 132,384 shares during the period. Finally, Geode Capital Management LLC boosted its position in Hims & Hers Health by 12.4% during the 4th quarter. Geode Capital Management LLC now owns 5,509,764 shares of the company’s stock worth $183,485,000 after buying an additional 608,950 shares during the period. 63.52% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

HIMS has been the topic of several recent research reports. Citigroup lifted their target price on shares of Hims & Hers Health from $24.00 to $28.00 and gave the stock a “neutral” rating in a research report on Tuesday, May 12th. Needham & Company LLC lifted their target price on shares of Hims & Hers Health from $30.00 to $35.00 and gave the stock a “buy” rating in a research report on Tuesday, May 12th. Weiss Ratings downgraded shares of Hims & Hers Health from a “hold (c)” rating to a “sell (d)” rating in a research report on Tuesday, May 12th. UBS Group set a $23.00 target price on shares of Hims & Hers Health in a research report on Friday, May 22nd. Finally, Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and set a $25.00 target price on shares of Hims & Hers Health in a research report on Tuesday, May 5th. Four equities research analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, Hims & Hers Health has an average rating of “Hold” and a consensus target price of $28.70.

Hims & Hers Health Stock Up 3.4%

Shares of NYSE HIMS opened at $27.08 on Tuesday. The company has a market capitalization of $6.27 billion, a P/E ratio of -300.88, a price-to-earnings-growth ratio of 49.14 and a beta of 2.37. Hims & Hers Health, Inc. has a 52-week low of $13.74 and a 52-week high of $70.43. The company has a debt-to-equity ratio of 2.18, a quick ratio of 1.56 and a current ratio of 1.69. The company’s 50 day moving average price is $24.73 and its 200-day moving average price is $26.96.

Hims & Hers Health (NYSE:HIMS) last issued its quarterly earnings results on Monday, May 11th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.44). The firm had revenue of $608.10 million during the quarter, compared to analyst estimates of $616.84 million. Hims & Hers Health had a positive return on equity of 6.10% and a negative net margin of 0.56%.The firm’s revenue for the quarter was up 3.8% on a year-over-year basis. During the same quarter last year, the firm posted $0.20 EPS. Equities analysts forecast that Hims & Hers Health, Inc. will post 0.04 earnings per share for the current year.

Insider Transactions at Hims & Hers Health

In other news, COO Michael Chi sold 97,289 shares of Hims & Hers Health stock in a transaction on Tuesday, March 17th. The shares were sold at an average price of $24.69, for a total value of $2,402,065.41. Following the completion of the sale, the chief operating officer owned 407,282 shares in the company, valued at $10,055,792.58. The trade was a 19.28% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Soleil Boughton sold 9,463 shares of Hims & Hers Health stock in a transaction on Monday, April 20th. The shares were sold at an average price of $30.00, for a total transaction of $283,890.00. Following the completion of the sale, the insider owned 299,368 shares of the company’s stock, valued at $8,981,040. This represents a 3.06% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 212,807 shares of company stock worth $5,473,644. Company insiders own 11.76% of the company’s stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.